Achaogen, Inc. (NASDAQ:AKAO) – Equities researchers at Leerink Swann dropped their Q4 2017 EPS estimates for shares of Achaogen in a note issued to investors on Wednesday. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will post earnings of ($0.99) per share for the quarter, down from their previous estimate of ($0.97). Leerink Swann currently has a “Outperform” rating and a $22.00 price target on the stock. Leerink Swann also issued estimates for Achaogen’s Q1 2018 earnings at ($1.03) EPS, Q2 2018 earnings at ($0.91) EPS, Q3 2018 earnings at ($0.90) EPS, Q4 2018 earnings at ($0.74) EPS, FY2018 earnings at ($3.56) EPS and FY2019 earnings at ($1.91) EPS.

AKAO has been the subject of several other research reports. BidaskClub lowered shares of Achaogen from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded shares of Achaogen from a “sell” rating to a “hold” rating and set a $27.00 target price for the company in a research note on Monday, July 17th. Guggenheim started coverage on shares of Achaogen in a research note on Tuesday, October 24th. They issued a “buy” rating and a $17.00 target price for the company. Mizuho started coverage on shares of Achaogen in a research note on Wednesday, September 6th. They issued a “buy” rating and a $28.00 target price for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 target price on shares of Achaogen in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. Achaogen has a consensus rating of “Buy” and an average target price of $25.78.

ILLEGAL ACTIVITY WARNING: “Brokers Set Expectations for Achaogen, Inc.’s Q4 2017 Earnings (AKAO)” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/brokers-set-expectations-for-achaogen-inc-s-q4-2017-earnings-akao/1701980.html.

Shares of Achaogen (NASDAQ:AKAO) opened at $13.01 on Monday. Achaogen has a one year low of $4.67 and a one year high of $27.79. The company has a current ratio of 6.99, a quick ratio of 6.99 and a debt-to-equity ratio of 0.08.

Achaogen (NASDAQ:AKAO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.13). Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The firm had revenue of $0.58 million during the quarter, compared to the consensus estimate of $2.09 million. During the same quarter in the previous year, the company earned ($0.41) EPS. The business’s revenue was down 96.4% compared to the same quarter last year.

In related news, COO Blake Wise sold 3,576 shares of the stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total transaction of $57,180.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.36% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. University of Notre Dame DU Lac grew its position in Achaogen by 49.9% during the third quarter. University of Notre Dame DU Lac now owns 155,654 shares of the biopharmaceutical company’s stock valued at $2,483,000 after buying an additional 51,786 shares during the period. Schwab Charles Investment Management Inc. grew its position in Achaogen by 154.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 122,684 shares of the biopharmaceutical company’s stock valued at $1,957,000 after buying an additional 74,384 shares during the period. Wells Fargo & Company MN grew its position in Achaogen by 34.3% during the third quarter. Wells Fargo & Company MN now owns 33,213 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 8,483 shares during the period. TimesSquare Capital Management LLC grew its position in Achaogen by 25.1% during the third quarter. TimesSquare Capital Management LLC now owns 1,361,665 shares of the biopharmaceutical company’s stock valued at $21,719,000 after buying an additional 273,365 shares during the period. Finally, Artal Group S.A. boosted its position in Achaogen by 25.0% during the third quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $3,988,000 after purchasing an additional 50,000 shares during the period. Institutional investors own 83.81% of the company’s stock.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Earnings History and Estimates for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.